Press Release: ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors
ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha…
Accord Plasma B.V. Expands Global Plasma Therapy Capabilities with Acquisition of Prothya Biosolutions
LONDON, Oct. 20, 2025 /PRNewswire/ -- Accord Plasma B.V., a subsidiary of Intas…
Contemporary Care Introduces TMS Therapy to Naples, Florida
Image by Contemporary Care NAPLES, Fla., Oct. 03, 2025 (GLOBE NEWSWIRE) --…
FDA approves Roches Tecentriq plus lurbinectedin as first-line maintenance therapy for extensive-stage small cell lung cancer
Combination reduced the risk of disease progression or death by 46% and…
Cirrus Therapeutics Raises $11 M Seed Financing to Advance Novel Ocular Gene Therapy to Reverse Underlying Age-Related Cause of Dry AMD
October 02, 2025 10:00 ET | Source: Cirrus Therapeutics, Inc. Cirrus’ lead…
Philips unveils latest CT and MR innovations in radiation therapy, advancing precision cancer care at ASTRO 2025
September 26, 2025 New Rembra RT and Areta RT CT platforms drive…
Advanced CAR-T Cell Therapy in a Young Engineer Battling High-Risk Pre-B Acute Lymphoblastic Leukemia
KOLKATA, India, Sept. 25, 2025 /PRNewswire/ -- In a major milestone for…
Roche enters into a definitive merger agreement to acquire 89bio, and its phase 3 FGF21 analog for the therapy of moderate to severe MASH
89bio’s pegozafermin allows for a potentially best-in-disease treatment for moderate to severe…
Booking Health Expands Access to Dendritic Cell Therapy After Study Confirms Survival Benefit in Glioblastoma Patients
September 09, 2025 13:19 ET | Source: Booking Health Langenfeld, Germany, Sept.…
Boehringers HERNEXEOS approved in China as first oral targeted therapy for previously treated patients with HER2-mutant advanced NSCLC
This press release is not intended for UK and US media. HERNEXEOS® (zongertinib…
